Flagship Pioneering: Difference between revisions
→External links: ce |
→External links: add tempalates |
||
| Line 25: | Line 25: | ||
==External links== |
==External links== |
||
*[https://www.statnews.com/2021/02/16/flagship-pioneering-profile/ At Flagship Pioneering, the brazen venture capital firm that bankrolled Moderna, there’s a tolerance for failure but not for weakness] (''[[Stat (website)|Stat]]'', February 2021) |
*[https://www.statnews.com/2021/02/16/flagship-pioneering-profile/ At Flagship Pioneering, the brazen venture capital firm that bankrolled Moderna, there’s a tolerance for failure but not for weakness] (''[[Stat (website)|Stat]]'', February 2021) |
||
{{Private equity and venture capital}} |
|||
{{Private equity firms}} |
|||
{{authority control}} |
{{authority control}} |
||
Revision as of 15:02, 23 February 2021
| Company type | Private |
|---|---|
| Founded | 1999 |
| Headquarters | , United States |
Key people |
|
| Website | www |
Flagship Pioneering is an American life sciences company based in Cambridge, Massachusetts[1][2][3] that invests in biotechnology, life sciences, health and sustainability companies.[4] Its portfolio companies include the American biotechnology company, Moderna.[5] The firm both funds and incubates companies.[6]
History
The company was founded in Cambridge in 1999 by Noubar Afeyan under the name NewcoGen (short for "new company generation"), but later changed its name to Flagship Ventures, and again in 2016 to Flagship Pioneering.[2]
In late 2010, Flagship formed Moderna, which focused on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA (mRNA) technology.[5][7]
References
- ^ Fry, Erika (May 19, 2020). "How the biotech investor behind Moderna is using the 'immigrant mindset' to take on COVID-19". Fortune.
- ^ a b Stendahl, Max (December 15, 2016). "A new name and new fund will ensure Cambridge's Flagship 'feels like a startup'". Boston Business Journal.
- ^ Saltzman, Jonathan (April 2, 2020). "VC firm Flagship Pioneering raises $1.1b for biotech startups, despite reeling economy". Boston Globe.
- ^ National Research Council, Division on Earth and Life Studies, Board on Chemical Sciences and Technology, Committee on Challenges in Chemistry Graduate Education (2012). Challenges in Chemistry Graduate Education: A Workshop Summary. National Academies Press. p. 42. ISBN 978-0-309-25708-4.
{{cite book}}: CS1 maint: multiple names: authors list (link) - ^ a b Dunn, Andrew (May 23, 2020). "The untold story of Moderna as the biotech's coronavirus vaccine faces a test that could make it one of the most consequential startups of all time". Business Insider.
- ^ DeAngelis, Allison (April 2, 2020). "With $1.1B in hand, life sciences investor Flagship rewrites its rulebook". Boston Business Journal.
- ^ Garde, Damian (November 10, 2020). "The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race". Stat.
External links
- At Flagship Pioneering, the brazen venture capital firm that bankrolled Moderna, there’s a tolerance for failure but not for weakness (Stat, February 2021)
  | This article about a private equity or venture capital firm based in the United States is a stub. You can help Wikipedia by expanding it. |